Atlas Trials

Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia

Clinical trial NCT05971251 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05971251
Sponsor
University of Alabama at Birmingham
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Chronic Lymphocytic Leukemia
Start date
2023-12-18
Primary completion
2026-12-31
Enrollment
24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.